Pancreatic cancer is currently one of the most lethal diseases. In recent years, increasing
evidence has shown that reprogrammed metabolism may play a critical role in the …

Pancreatic cancer (PC) has one of the highest fatality rates and the currently available
therapeutic options are not sufficient to improve its overall poor prognosis. In addition to …

Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of
cancer-related death. The high mortality rate results from a lack of methods for early …

Pancreatic cancer is a highly deadly disease: almost all patients develop metastases and
conventional treatments have little impact on survival. Therapeutically, this tumor is poorly …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies with an
extremely poor prognosis. Energy metabolism reprogramming, an emerging hallmark of …

Pancreatic ductal adenocarcinoma, an aggressively invasive, treatment-resistant
malignancy and the fourth leading cause of cancer deaths in the United States, is usually …

Targeting cancer metabolism has emerged as a hot topic for drug discovery. Most cancers
have a high demand for metabolic inputs (ie glucose/glutamine), which aid proliferation and …

Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a long-term survival
rate under 10%. Available cytotoxic chemotherapies have significant side effects, and only …

Pancreatic ductal adenocarcinoma is prone to distant metastasis and is expected to become
the second leading cause of cancer-related death. In an extremely nutrient-deficient and …

Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading
cause of cancer death by 2030. Current therapeutic options are limited, warranting an urgent …